Sector News

Novo Nordisk A/S: Changes in Novo Nordisk’s Executive Management

November 25, 2014
Life sciences
(GLOBE NEWSWIRE) – Following a change in the distribution of responsibilities among the members of its Executive Management, Novo Nordisk has reduced the number of executives from seven to six. In this connection Executive Vice President and Chief of Staffs Lise Kingo has decided to leave Novo Nordisk.
 
Her areas of responsibility will be taken over by other members of Executive Management. As from today:
 
– Corporate People & Organisation and Business Assurance report to Lars Fruergaard Jørgensen
– Corporate Stakeholder Engagement reports to Jakob Riis
– Corporate Communications reports to Lars Rebien Sørensen.
 
Commenting on the changes, Lars Rebien Sørensen, CEO, says: “I would like to thank Lise for her many contributions to Novo Nordisk during her impressive career in the company. Of special note is her leadership in driving the company’s strategy within sustainable development, corporate branding and public affairs, which has earned Novo Nordisk recognition as a respected global business. I wish her the best of luck in the future.”
 
Lise Kingo says: “I have really enjoyed being part of Novo Nordisk throughout my career, not least during my time as a member of its Executive Management. It has been a fantastic journey and I wish the company and my colleagues all the best in their onward journey. This is the beginning of a new chapter in which I plan to utilise my experience and insights in boards of companies and organisations internationally.”
 
Following the above-mentioned changes, Novo Nordisk’s Executive Management is now composed as follows:
 
Lars Rebien Sørensen, CEO (chief executive officer).
 
Kåre Schultz, president and COO (chief operating officer), responsible for Sales and Product Supply.
 
Jesper Brandgaard, executive vice president and CFO (chief financial officer), responsible for Finance, Legal, and Investor Relations.
 
Lars Fruergaard Jørgensen, executive vice president, responsible for Corporate IT, Corporate Quality, Corporate Development, Corporate People & Organisation and Business Assurance.
 
Jakob Riis, executive vice president, responsible for Marketing, Medical Affairs and Corporate Stakeholder Engagement. 
 
Mads Krogsgaard Thomsen, executive vice president and chief science officer, responsible for Research, Development and Regulatory Affairs.
 
Source: Novo Nordisk
 

Related News

April 17, 2021

Thermo Fisher to buy research contractor PPD in $17B deal

Life sciences

Thermo Fisher Scientific plans to buy PPD for $17.4 billion to bolster its clinical research service offerings to pharmaceutical and biotech companies.

April 17, 2021

Nestlé finds supplement cocktail slashes preterm birth in major preconception study

Life sciences

Nestlé Research has linked a specific blend of myo-inositol (a type of sugar), probiotics, riboflavin, zinc and vitamins D, B6 and B12 to the decreased incidence of preterm birth when consumed before and during pregnancy.

April 17, 2021

Eli Lilly, riding pharma’s rising digital wave, drafts Apple exec to replace Shah as CDO

Life sciences

Eli Lilly hired a new digital chief from Apple in another consumer switch for pharma and as the industry speeds up its shift to online strategies.

Send this to a friend